These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 15123532

  • 1. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
    Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S.
    Circulation; 2004 May 11; 109(18):2197-202. PubMed ID: 15123532
    [Abstract] [Full Text] [Related]

  • 2. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
    Arcavi L, Behar S, Caspi A, Reshef N, Boyko V, Knobler H.
    Am Heart J; 2004 Feb 11; 147(2):239-45. PubMed ID: 14760320
    [Abstract] [Full Text] [Related]

  • 3. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
    Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S.
    Eur Heart J; 2005 Oct 11; 26(19):2032-8. PubMed ID: 15872029
    [Abstract] [Full Text] [Related]

  • 4. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
    Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S.
    Arch Intern Med; 2005 May 23; 165(10):1154-60. PubMed ID: 15911729
    [Abstract] [Full Text] [Related]

  • 5. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
    Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S.
    Arch Intern Med; 2006 Apr 10; 166(7):737-41. PubMed ID: 16606809
    [Abstract] [Full Text] [Related]

  • 6. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
    Haim M, Benderly M, Tanne D, Matas Z, Boyko V, Fisman EZ, Tenenbaum A, Zimmlichman R, Battler A, Goldbourt U, Behar S.
    Am Heart J; 2007 Dec 10; 154(6):1095-101. PubMed ID: 18035081
    [Abstract] [Full Text] [Related]

  • 7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 10; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 8. Smoking and development of type 2 diabetes in patients with decreased functional capacity.
    Tenenbaum A, Fisman EZ, Adler Y, Motro M, Boyko V, Behar S.
    Int J Cardiol; 2005 Oct 10; 104(3):275-81. PubMed ID: 16186056
    [Abstract] [Full Text] [Related]

  • 9. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S.
    Am J Cardiol; 2009 Jan 01; 103(1):41-5. PubMed ID: 19101227
    [Abstract] [Full Text] [Related]

  • 10. Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity.
    Miller M.
    Nat Clin Pract Endocrinol Metab; 2006 Apr 01; 2(4):198-9. PubMed ID: 16932284
    [No Abstract] [Full Text] [Related]

  • 11. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.
    Sidhu JS, Cowan D, Tooze JA, Kaski JC.
    Am Heart J; 2004 Jun 01; 147(6):e25. PubMed ID: 15199366
    [Abstract] [Full Text] [Related]

  • 12. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis.
    Fisman EZ, Motro M, Tenenbaum A, Boyko V, Mandelzweig L, Behar S.
    Am Heart J; 2001 Mar 01; 141(3):485-90. PubMed ID: 11231448
    [Abstract] [Full Text] [Related]

  • 13. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
    Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, Nakai Y.
    Metabolism; 2001 Apr 01; 50(4):477-80. PubMed ID: 11288046
    [Abstract] [Full Text] [Related]

  • 14. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC, Schwartz S, Rosenberg MA, Jariwala N, Becker RH, Johnston PS.
    Exp Clin Endocrinol Diabetes; 2008 May 01; 116(5):282-8. PubMed ID: 18484560
    [Abstract] [Full Text] [Related]

  • 15. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
    Brodov Y, Behar S, Boyko V, Chouraqui P.
    Am J Cardiol; 2010 Dec 15; 106(12):1717-20. PubMed ID: 21126615
    [Abstract] [Full Text] [Related]

  • 16. Factors related to the development of diabetes during a 20-year follow-up. A prospective study in a homogeneous group of middle-aged men.
    Strandberg TE, Salomaa V.
    Nutr Metab Cardiovasc Dis; 2000 Oct 15; 10(5):239-46. PubMed ID: 11213532
    [Abstract] [Full Text] [Related]

  • 17. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
    Goldenberg I, Benderly M, Goldbourt U, BIP Study Group.
    J Am Coll Cardiol; 2008 Jan 29; 51(4):459-65. PubMed ID: 18222357
    [Abstract] [Full Text] [Related]

  • 18. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis.
    Nichols GA, Hillier TA, Brown JB.
    Am J Med; 2008 Jun 29; 121(6):519-24. PubMed ID: 18501234
    [Abstract] [Full Text] [Related]

  • 19. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 29; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 20. Relative role of major risk factors for Type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up.
    Cicero AF, Dormi A, Nascetti S, Panourgia MP, Grandi E, D'Addato S, Gaddi A.
    Diabet Med; 2005 Sep 29; 22(9):1263-6. PubMed ID: 16108859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.